were defined using a tumor-to-blood ratio>1.4. For FDG-high fraction and high volume a SUV>50% of SUV max was 60 used. We evaluated the spatial correlation between HX4 and FDG uptake within the tumor, to quantify the (mis)match between volumes with a high FDG and high HX4 uptake.
Introduction
Lung cancer has the highest death rate among leading cancer types (1). Standard treatment for advanced stage non-small cell lung cancer (NSCLC) is the combination of radiotherapy (RT) and chemotherapy, administered either sequentially or concurrently (2) . Tumor cell hypoxia has a negative impact on cancer treatment effectiveness, it 75 promotes resistance to radiotherapy (RT) and chemotherapy, increases the metastatic potential, and is therefore related to a poor prognosis (3-5). Tumor hypoxia is present in the majority of NSCLCs, which can be visualized and quantified using functional PET imaging with radiolabeled 2-nitroimidazoles (6, 7). In standard clinical practice, a combination of anatomic computed tomography (CT) and functional [ 18 F]fluorodeoxyglucose (FDG) PET imaging is frequently used to visualize, detect and stage malignancies. In addition, FDG PET can be used to identify subvolumes with a high metabolism, which are more susceptible to local 85 recurrence after (chemo)radiotherapy (11, 12) . Aerts et al. showed that the residual tumor volume after RT is mainly located within the pre-RT high FDG-uptake volume. However, 30% of the residual volume did not correspond to the high FDG volume (11, 13) . This may be caused by tumor regrowth in pre-RT hypoxic tumor subvolumes located outside the high FDG volume. Therefore, it is of great interest to investigate the correlation between both unfavorable biological features (high tumor metabolism, hypoxia) since they can be used to predict 90 treatment outcome. In addition, imaging-derived tumor features have the potential to guide treatment with hypoxic modifiers or radiotherapy dose-painting (14) (15) (16) . The uptake of FDG in the cell is dependent on the overexpression of glucose transporters (GLUT), which can be upregulated in the absence of oxygen, through the HIF1α-mediated pathway (17). This may suggest a possible overlap between volumes of high FDG uptake and tumor hypoxia, even though they represent different biological properties of tumors.
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The aim of this study was to perform an extensive comparison of tumor metabolism, using FDG, and hypoxia, using HX4, to fully characterize the relationship between both PET tracers on a global tumor and voxel level for primary NSCLC and the regional lymph node metastases.
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Research. 
Materials and Methods

Patients
FDG and HX4 PET/CT images of 25 NSCLC patients (17 male, 8 female) were acquired before the start of external beam radiotherapy. The average age of the patients was 63y (range 40-82y). Tumor stage ranged from IIB-IV, pathology being adenocarcinoma (N=13), squamous cell carcinoma (N=5), large cell carcinoma (N=7). Patients were 105 treated with radical radiotherapy (N=3) or chemo-radiation (N=22), with the majority of patients receiving at least one cycle of chemotherapy before PET imaging and before the start of radiotherapy (Supplementary Table S1 ). PET data were acquired in the translational research part of two phase II trials [PET-Boost, NCT01024829 (18); Nitroglycerin (NCT01210378)], both having identical PET imaging procedures. The clinical trials were approved by the appropriate medical ethical review committee, and all patients provided written informed consent before study 110 entry. 
PET/CT imaging
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The injected activity of FDG depended on the patient's weight according to the national guidelines (20) . PET/CT imaging was performed one hour after intravenous administration of FDG. FDG PET/CT scans were acquired using a 
Analysis
For all patients, gross tumor volumes (GTVs), including the primary lesion (GTVprim) and involved lymph nodes 135 (GTVln), were defined on the FDG PET/CT scan by two experienced radiation oncologists in consensus. GTVprim and GTVln were analyzed separately. Lesions with a size <5 cm 3 were excluded due to potential partial volume effects.
The FDG PET/CT was rigidly registered to the HX4 PET/CT using registration software developed in-house. The rigid transformation was determined by the registration of the FDG-CT to the HX4-CT; the same transformation was subsequently applied to the FDG PET scan and the GTVs. A volume of interest in the aorta was defined as 140 background region.
The maximum and mean standardized uptake values (SUV max and SUV mean ), corrected for body weight, were determined within the GTV for both FDG and HX4 PET. For the HX4 PET, calculations were made of the maximum tumor-to-blood ratio (TBR max ), defined as the SUV max in the tumor divided by the SUV mean in the aorta, the HX4 highfraction (HX4-HF) and HX4 high-volume (HX4-HV), both defined as the fraction/volume of the GTV with a TBR>1.4. 
Results
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Overall correlation of FDG and HX4 parameters
This study analyzed the overall FDG and HX4 uptake in the primary tumor and lymph nodes of 25 NSCLC patients.
All GTVprim (N=25) and 19 GTVln were larger than 5 cm 3 and all were used for the analysis. The average values of the GTV, FDG and HX4 parameters are shown in Table 1 . The sub-classification, based on tumor pathology, showed no significant differences for any of the FDG or HX4 parameters (examples are shown in supplementary Figure S1 ).
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The FDG-HV was larger than the HX4-HV in 24/25 GTVprim and in all GTVln. Potential correlations between FDG and HX4 PET based parameters were investigated.
The correlation coefficients for the primary tumors are shown in Table 2 For the involved lymph nodes GTVln volume has a large effect on the correlation coefficients between the HX4 and FDG parameters (Supplementary Table 2 ). The multiple linear regression using GTVln volume and FDG-SUV max to predict HX4-HV (R=0.96) therefore only showed a significant contribution for the GTVln volume (p<0.001) and not for FDG-SUV max (p=0.26).
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Average distribution of FDG and HX4 uptake
The average distribution within the primary tumor based on the four previously predefined categories is shown in Table 3 and visualized in Figure 2A . On average, the FDG high volume is 42±21% of the GTVprim, of which 10±12% is hypoxic. On average, 3% (range: 0-31%) of the GTVprim is hypoxic but outside the FDG-HV, representing 24%
(3.2%/13.6%) of the total hypoxic volume.
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The effect of alternative thresholds on the average distribution of FDG and HX4 within the primary tumor is shown in Supplementary Table S3 and visualized Based on the voxel-wise analysis we observed that in 10 lesions, less than 1 cm 3 of the HX4-HV was outside the FDG-HV (group 1, Figure 3A ). In 7 lesions, 2-12 cm 3 of the HX4-HV was outside the FDG-HV (group 2, Figure 3B ).
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Finally, in 2 patients a clearly distinct uptake pattern was observed between the two tracers and hypoxic volumes of 46 cm 3 and 102 cm 3 were observed outside the FDG high uptake region, which were 73% and 78% of the total HX4-HF, respectively (group 3, Figure 3C ). The primary tumor volume was significantly correlated to the group the lesion was assigned to (R=0.75; p<0.01).
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Discussion
This study was initiated to assess the correlation of (spatial) uptake patterns of hypoxia (using HX4 PET) and tumor metabolism (using FDG PET) in primary NSCLC and associated lymph node metastases. (29) investigated in NSCLC patients the use of nitroglycerin (an organic nitrate which causes vasodilatation, increased blow flow and reduces the expression of HIF1-α) in combination with chemo-radiation. In this study promising response rates were observed, however, there was also (mild) increased toxicity (e.g. headache, hypotension) due to nitroglycerin administration. Another promising compound is the hypoxia activated prodrug 235 TH-302 which releases bromo isophosphoramide mustard, a potent DNA alkylating agent, in hypoxic regions. Saggar et al. (30) recently demonstrated that TH-302 administered togheter with chemotherapy enhances the antitumor effect but also increases toxicity. From these recent studies we acknowledge the therapeutic effect of additional anti-hypoxia treatment, but also the importance to limit unnecessary toxicity by selecting patients who will benefit from these modifications. We show that we can non-invasively visualize and quantify tumor hypoxia, 240 using HX4 PET, in patients with NSLSC. In addition, our results show that patients with a larger tumor size and higher FDG uptake are more likely to have a larger hypoxic volume. This combination (GTV size and FDG uptake) could be used as a surrogate for hypoxia PET imaging, however, despite the correlation between hypoxia and FDG parameters, the distinction between hypoxic and non-hypoxic tumors based on FDG PET can be misleading, since non-hypoxic tumors are present in a broad range of FDG uptake (FDG-SUV max : 3.5 -17.5 also shown in Figure 1B) . It is important to note that a correlation at a global tumor level provides no information about the intratumoral heterogeneity. At the moment, limited data is available concerning the correlation of hypoxia PET and FDG PET at a subvolume (e.g. voxel) level in NSCLC (7, 31) . The spatial concordance and discordance of both PET modalities is of interest for radiotherapy boosting strategies. FDG PET is already used in the context of clinical trials to boost highly metabolic tumor subvolumes (18, 32) . We hypothesize that hypoxia PET imaging may be more selective in defining 250 radioresistant voxels within the GTV, and can provide complementary information regarding the definition of radiotherapy boost volumes. A voxel-wise comparison was performed to evaluate the spatial distribution of the HX4 and FDG uptake. A reasonable correlation between both tracers was observed in the majority of patients. This is in contradiction to the previous published results of Bollineni et al. (7), who observed no correlation between with an adenocarcinoma of the lung, which was not present in squamous cell carcinomas (SCC) patients. Also, they observed a difference in intra-tumoral distribution between adenocarcinoma and SCC, which was not observed in our cohort of NSCLC patients. It is well described that hypoxia leads to an increased uptake of glucose through 260 various molecular mechanisms (33) . Nevertheless, an increased glycolysis is also observed without hypoxia, e.g. by c-myc aberrations (34) . From a molecular point of view, it is therefore logical that FDG uptake and hypoxia is partially overlapping and is highly dependent on the genetics of the tumour.
Thresholds were defined arbitrarily to define regions with a high or low uptake on both FDG and HX4 PET. The high 265 FDG PET volume was defined based on the ongoing NSCLC boost trial (18) , whereas the high HX4 region was based on previous publications, indicating that a threshold of TBR>1.4 is rational to define hypoxia (6, 8, 35, 36) . These thresholds showed the HX4 high volume to be three times smaller on average than the FDG high volume.
This work can be used in clinical setting to divide patients with a hypoxic lesion into different groups, stratifying lesions with an agreement or disagreement between the HX4 and FDG PET uptake pattern. In the patients with an 270 concordance, the use of HX4 PET has limited additional value for the selection of the radiotherapy boost volume, however, this volume could be limited to HX4 high areas only, facilitating further dose escalation without comprising the surrounding healthy tissue. In other patients a (partial) discordance between the HX4 and FDG PET uptake pattern was observed. In these patients, the boost region could be adjusted to either HX4 PET or a combination of HX4 and FDG PET with the aim to improve loco-regional control. Based on the current analysis, a 275 radiation boost to the FDG high area (SUV>50% SUV max ) would on average miss 24% of the hypoxic volume, which seems in agreement with the residual activity after RT outside the high-FDG area as reported by Aerts et al. (11) .
Previous studies have already shown that radiotherapy dose distribution based on tumor hypoxia is possible and promising (37, 38) . Currently there are strategies available to investigate the original location of local recurrences inside the tumor volume (39) . These studies will characterize the subvolumes inside the heteregenous tumour that are difficult to control. Ultimately, the effect of tumour subvolume characterization and targeting, by radiotherapy or other therapeutic interventions, needs to be assessed in a randomized trial This study has several limitations. First, most patients received chemotherapy before the start of radiotherapy and PET imaging. Chemotherapy can reduce the amount of tumor hypoxia and downregulates metabolism, resulting in a decreased uptake of HX4 and FDG (40). However, the focus of our research is on the correlation between both 285 imaging modalities, therefore treatment differences between patients are less relevant. In addition, it is most important to have recent PET information before the start of (adaptive) radiotherapy. Second, we were not able to validate the current imaging observations on tumor specimens. Nevertheless, van Baardwijk et al. (41) showed previously that FDG-PET imaging is correlated to GLUT-1 and HIF-1α expression in NSCLC patients and Dubois et al.
(8) showed a high correlation between HX4 PET uptake and pimonidazole staining in a rat rhabdomyosarcoma 290 model. Third, the study acquired PET scans in free-breathing, which might cause blurring of the PET signal.
Although, since both the FDG and HX4 scans were obtained in this setting, we do not expect any substantial bias for the comparison. Furthermore, advanced stage tumors are known to show little breathing induced motion (42, 43) .
Fourth, the FDG PET/CT was rigidly registered to the HX4 PET/CT scan to compare spatial uptake patterns. Small errors in registration can have a significant effect on correlation (44) . However, patients in the current study were 295 aligned in radiotherapy treatment position providing a strong basis for accurate registration. Fifth, there was a small time interval between the FDG and HX4 PET/CT scan. Changes in anatomy, tumor metabolism or hypoxia may have occurred in this interval and influenced the comparison results. The time interval in our study was short (median: 3 days) and no interventions (e.g. chemotherapy or radiotherapy) were performed between the two scans, limiting the chances of anatomical or physiological changes. Finally, the usability of a tracer for radiation 300 dose-painting is dependent on its spatial reproducibility. Aerts et al. (45) showed that the location of low and high FDG volumes were stable during radiotherapy. The short time reproducibility for HX4 (2h vs. 4h) was confirmed, but the long term reproducibility is still unknown (6) . However, a high reproducibility has been reported by Busk 
